![]() Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis. ![]() Merck has the meaning set forth in the preamble. GSK means the generation shift key as defined in Article 2(12) of the CACM Regulation Novartis shall have the meaning set forth in the Preamble. The Debentures shall bear interest from the date of issue at the rate of 12% per annum (based on a year of 360 days composed of twelve 30-day months).Ĭollaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)). In connection with the performance obligations under the uniQure Agreement, the founders of 4D Molecular Therapeutics, LLC received equity options to purchase an aggregate of 609,744 of uniQure ordinary shares that vested over the initial three-year term of the agreement.ĭirector (UC Case No.: B03-104) To LICENSEE: 4D Molecular Therapeutics LLC 000 Xxxxxxx Xxxxxx Mill Valley, CA 94941 Attn.: Either party may change its address upon written notice to the other party. Thirdly, since it is a case in which there had been only one material factor operating at the time of the claimant’s appointment at a lower salary than that of her male comparators, and that material factor had ceased, the result of the case seems obvious (though I do note that the claimant had failed in both the ET and the EAT). It is estimated that 196 million people will be affected by AMD worldwide by 2020 according to a study published in Lancet Global Health.Key milestones achieved over the last 12 months and next steps include:oIn November 2014, the Company entered into a collaboration with 4D Molecular Therapeutics (4DMT) to identify novel AAV capsids, the protein shell that helps deliver our ddRNAi constructs into retinal cells. Other assets determined to be restricted by the Division.Requirements for AdSSs with Restricted EquityIf AdSS’s equity is not supported by unrestricted cash or investments, and the AdSS does not meet the equity per member requirements, then the AdSS may be required to maintain a Performance Bond in an amount greater than 100% of one month’s capitation to cover the amount of the equity necessary to meet the requirements. In addition, in January 2014 the Company granted another 609,744 options to the management of 4D Molecular Therapeutics.ĭirector (UC Case No.: B13-135) To LICENSEE: 4D Molecular Therapeutics LLC 000 Xxxxxxx Xxxxxx Mill Valley, CA 94941 Attn.: Either party may change its address upon written notice to the other party. ![]() SCHEDULE 13G ITEM 1(a) NAME OF ISSUER: 4D Molecular Therapeutics, Inc. REGISTERED OFFICE.The registered office of 4D Molecular Therapeutics, Inc. Each of Benitec and 4D Molecular shall be a “ Party” or collectively, the “Parties.” BACKGROUND: Benitec is a biopharmaceutical company focused on researching, developing, making, marketing and selling biotechnology products using gene silencing technology, including in particular its ddRNAi technology 4D Molecular is a biopharmaceutical company focused on discovering and developing novel adeno- associated viral vectors optimized for delivery of nucleic acids to specific types of target cells Benitec and 4D Molecular would like to collaborate to identify and develop adeno-associated virus (“AAV”) vector variants optimized for gene delivery to tissues within the eye using 4D technology and products combining such optimized AAV vector variants with Benitec’s ddRNAi technology, for further development and commercialization by Benitec under license from 4D Molecular and 4D Molecular and Benitec are entering into this Agreement to set out the terms governing the research collaboration.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |